More sexual partners may increase risk of prostate cancer

July 02, 2001

CHAMPAIGN, Ill. -- Men should already know that sex with multiple partners, especially unprotected sex, can increase their risk of contracting HIV and various venereal diseases.

They also can add that it may raise their odds of getting prostate cancer in middle age, according to a study published in a recent issue of the American Journal of Epidemiology.

The study, titled "Sexual Factors and the Risk of Prostate Cancer," was written by Karin Rosenblatt, a professor of community health at the University of Illinois; and Janet Stanford and Kristine Wicklund, researchers in the Program in Epidemiology at the Fred Hutchinson Cancer Research Center in Seattle. In it, the authors wrote that their findings "suggest that there is a direct positive relationship between the number of lifetime female sexual partners and the risk of prostate cancer in middle-aged men." The findings are consistent with several previous studies, they noted, and "suggest that sexual behavior and associated exposure to sexually transmitted agents enhance the risk of prostate cancer." The study was based on a population-based interview survey of 1,456 men ages 40-64 in King County, Wash. The study group consisted of 753 men who had been diagnosed with prostate cancer between 1993 and 1996. They were identified by the Seattle-Puget Sound cancer registry, part of the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) Program.

The control group of 703 men was chosen using random-digit telephone dialing, with an age distribution similar to that of the study group.

The analysis showed a linear relationship between risk and number of female sexual partners, with those having 30 or more sexual partners shown to have more than twice the risk of having prostate cancer. (The respondents were asked to estimate their number of partners within the following ranges: 1, 2-4, 5-14, 15-29, and 30 or more.)

The authors established that relationship after controlling for factors such as age, age at first intercourse, race, family history of prostate cancer, and number of prostate specific antigen (PSA) tests in the past five years. They found no relationship between prostate cancer and frequency of intercourse.

Rosenblatt pointed out that though the numbers were cause for concern, they should not be overplayed. "I'm not sure we've figured out the mechanism with this, and also some studies don't show any association and some studies do, so I think there needs to be a little more research in this area." Similar studies on other cancers, however, such as cervical cancer, have shown even greater risk with the increase in number of sexual partners.
The interview survey was conducted by the Fred Hutchinson Cancer Research Center and was supported by a grant from the National Cancer Institute. The study, in the June 15 issue of the journal, can be found at the AJE Web site:

University of Illinois at Urbana-Champaign

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to